ArriVent BioPharma said its lead investigational lung cancer therapy furmonertinib failed its primary goal in a late-stage Phase 3 trial. The drug was evaluated as a first-line monotherapy in tumors with EGFR exon 20 insertion mutations. Company statements indicate furmonertinib did not meaningfully delay tumor progression versus chemotherapy and missed statistical significance. ArriVent said it will review the data to determine next steps. The outcome matters for investors and competitors because EGFR exon 20 insertion remains a crowded therapeutic area with multiple targeted options, and monotherapy results can influence whether sponsors shift toward combination regimens or patient selection refinements.